Sickle cell disease (SCD) is an umbrella term for a group of life‐long debilitating autosomal
recessive disorders that are caused by a single‐point mutation (Glu→ Val) that results in …

Sickle-cell disease (SCD) is an inherited hemoglobinopathy, causing lifelong complications
such as painful vaso-occlusive episodes, acute chest syndrome, stroke, chronic anemia, and …

Sickle cell disease is the most common inherited pathological haemoglobinopathy. Over the
past 30 years, disease-related morbidity and mortality have improved in high-income …

Sickle cell disease is an inherited blood disorder afflicting an estimated 100,000 individuals
in the United States and over 20 million people worldwide. The disease is heralded as the …

The importance of protecting brain function for people with sickle cell disease (SCD) cannot
be overstated. SCD is associated with multiple cerebrovascular complications that threaten …

β-Thalassemia and sickle cell disease are autosomal recessive disorders of red blood cells
due to mutations in the adult β-globin gene, with a worldwide diffusion. The severe forms of …

Introduction Sickle cell disease (SCD) is an inherited disorder characterised by
polymerisation of deoxygenated haemoglobin S and microvascular obstruction. The cardinal …

Hydroxyurea has been a mainstay of systemic management of SCD with prior work
suggesting its ability to reduce the likelihood of developing retinopathy. There are several …

Introduction Sickle cell disease (SCD) describes a group of heritable blood disorders
caused by the polymerization of sickle hemoglobin (HbS). HbS polymerization leads to …

Hydroxyurea, the first approved drug for sickle cell disease, decreases sickle hemoglobin
polymerization by inducing fetal hemoglobin. Its effects in young children are excellent; …